Aspirin™ can look back at a rich, long-standing history and exciting future. For 125 years, Aspirin™ has been empowering everyday health transformation for all. The proven role of Aspirin™ in OTC pain, inflammation, and fever management, as well as low-dose Aspirin™ Cardio for cardiovascular disease prevention, continues to make it a globally versatile and trusted brand.
“No other drug in the world has had such a fascinating and record-breaking history – a development that has not yet come to an end.”
Sir John Vane
Nobel Prize Winner
Source.
1. Who List of Essential Medications: 17th List, March, 2011. http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf (accessed March 22, 2013).
2. Weisman S, Graham D. Evaluation of the benefits and risks of low-dose Aspirin™ in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002;162(19):2197–2202.
3. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin™ in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomized clinical trials. Lancet 2009; 373:1849–1860.
4. Genton E, Barnett HJ, Fields WS et al. XIV. Cerebral ischemia: the role of thrombosis and of antithrombotic therapy. Study group on antithrombotic therapy. Stroke 1977;8(1):150–175.
5. Lewis HD Jr, Davis JW, Archibald DG et al. Protective effects of Aspirin™ against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309(7):396–403.
6. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of Aspirin™, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349(9065):1569–1581.
7. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N et al. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how Aspirin™ inhibits acute inflammation. J Exp Med 2004;200(1):69–78.
8. Lampl C, Voelker M, Steiner TJ. Aspirin™ is First-Line Treatment for Migraine and Episodic Tension-Type Headache Regardless of Headache Intensity. Headache 2012;52(1):48–56.
9. Voelker M.,Hammer M., Inflammopharmacology 2012;20:225-231.
10. Cooper SA., Voelker M., Inflammopharmacology 2012;20:225-242.
11. Bayer Internal Sales Report FY 2022.